Results 51 to 60 of about 6,300 (191)

Safety of Tirofiban in Acute Ischemic Stroke [PDF]

Stroke, 2011
Background and Purpose— Tirofiban is a highly selective, fast-acting nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist with a short half-life time. Glycoprotein IIb/IIIa antagonists are effective for the treatment of acute coronary syndromes proven in large clinical trials.
Siebler, M., Hennerici, M., Schneider, D., von Reutern , G., Seitz, R., Rother, J., Witte, O., Hamann, G., Junghans, U., Villringer, A., Fiebach, J.   +10 more
openaire   +4 more sources

Radiolabeled tirofiban – a potential radiopharmaceutical for detection of deep venous thrombosis

Drug Design, Development and Therapy, 2016
Marija Darkovska-Serafimovska,1,2 Emilija Janevik-Ivanovska,1 Icko Djorgoski,2 Zorica Arsova-Sarafinovska,1,3 Milka Zdravkovska,1 Trajan Balkanov,4 Nenad Ugresic5 1Department of Pharmacy, Faculty of Medical Sciences, Goce Delcev University, Stip ...
Darkovska-Serafimovska M, Janevik-Ivanovska E, Djorgoski I, Arsova-Sarafinovska Z, Zdravkovska M, Balkanov T, Ugresic N   +6 more
doaj  

Intravenous tirofiban therapy for patients with capsular warning syndrome [PDF]

Stroke and Vascular Neurology, 2019
BackgroundCapsular warning syndrome (CWS) is defined as recurrent episodes of transient ischaemic attacks ≥3 times during a short time frame. There is no effective therapy to stop these attacks. We, herein, report our experience of using intravenous tirofiban to treat CWS.MethodsAll patients with CWS in our hospital from January 2013 to September 2017 ...
Chun-Rong Liang, Zhi-Qiang Xu, Ya Wu, Shu-Han Huang, Wei Li, Xiao-Shu Li, Meng Zhang, Li-Li Zhang, Yan-Jiang Wang, Huan Wang, Cheng-Chun Liu   +10 more
openaire   +4 more sources

Influence of Tirofiban maintenance duration on patients with acute myocardial infarction treated by percutaneous coronary intervention

Chronic Diseases and Translational Medicine, 2015
Objective: To evaluate the efficacy and short term prognosis of Tirofiban in different treatment duration in patients with acute ST segment elevation myocardial infarction (STEMI) and percutaneous coronary intervention (PCI) combined with intracoronary ...
Zhen-Guo Ji, Hong-Bin Liu, Zhi-Hong Liu, Guo-Ping Ma, Li-Qiang Qin, Wei Dong, Li-Ya Wang   +6 more
doaj  

Tirofiban induced diffuse alveolar hemorrhage

IHJ Cardiovascular Case Reports (CVCR), 2018
Alveolar hemorrhage is a dreaded complication which is seen rarely following the use of tirofiban, it is often confused with other respiratory syndromes resulting in inappropriate or delayed treatment. We present a case of acute alveolar hemorrhage following tirofiban infusion following acute coronary syndrome.
Deepak Kadeli, K S Satish, R Keshava, Nagaraj Aithal   +3 more
openaire   +3 more sources

Effects of two different glycoprotein platelet IIb/IIIa inhibitors and the clinical endpoints in patients with intracranial Pipeline flow diverter implant

Journal of Interventional Medicine, 2020
Objective: To compare the antiplatelet effect and major adverse cerebrovascular events of Pipeline for intracranial aneurysms using glycoprotein IIb/IIIa antagonists (GPI) eptifibatide and tirofiban.
Qiao Deng, Shichao Zhang, Mingzhou Li, Guozhong Zhang, Wenfeng Feng   +4 more
doaj  

Cost-effectiveness of tirofiban for acute ischemic stroke without large or medium-sized vessel occlusion: A Markov modelling analysis from the Chinese and United States perspectives.

PLoS ONE
BackgroundThe RESCUE BT2 trial recently showcased the efficacy of tirofiban in treating acute ischemic stroke (AIS) without large or medium-sized vessel occlusion.
Li Wang, Yuhong Zeng, Limei Zhou, Ping Xu, Xianbin Guo, Yu Xie, Junxiu Cai, Min Pan, Jie Tang, Qingtao Gong, Rong Su, Yan Liu, Yake Lou   +12 more
doaj   +1 more source

In-Lab Upfront Use of Tirofiban May Reduce the Occurrence of No-Reflow During Primary Percutaneous Coronary Intervention. A Pilot Randomized Study

Arquivos Brasileiros de Cardiologia
Background: Despite successful opening of culprit coronary artery, myocardial reperfusion does not always follows primary percutaneous coronary intervention (PPCI).
Igor Matos Lago, Gustavo Caires Novaes, André Vannucchi Badran, Rafael Brolio Pavão, Ricardo Barbosa, Geraldo Luiz de Figueiredo, Moysés de Oliveira Lima Filho, Jorge Luiz Haddad, André Schmidt, José Antônio Marin Neto   +9 more
doaj   +1 more source

The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume

Scientific Reports
This study aimed to evaluate the safety and efficacy of intra-arterial (IA) administration of low- dose tirofiban during endovascular therapy in patients with large ischemic core volumes on initial brain CT. Patients were divided into two groups based on
Kwang-Chun Cho, Nak-Hoon Son, So Hyeon Gwon, Jin Wook Choi, Woo Sang Jung   +4 more
doaj   +1 more source

Tirofiban (Aggrastat®) [PDF]

Cardiovascular Drug Reviews, 1999
Frederick L. Sax and, Eliav Barr, Bohumil Bednar, Mark E. Duggan, Melissa S. Egbertson, Man-Wai Lo, Gail Murphy, Joseph J. Lynch, Jacquelynn J. Cook, Wasyl Halczenko, George D. Hartman, Lawrence I. Deckelbaum, Robert J. Gould   +12 more
openaire   +2 more sources